ArticleOncology letters2014
Prognostic role of
Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.Medicine · 2016Pooled it
- The Transcriptomic Profile Underlying Somatic MonoallelicDiagnostics (Basel, Switzerland) · 2025Article
- Treatment, outcomes, and resource utilization among patients with metastatic breast and advanced epithelial ovarian cancer, by BRCA1/2 and HRD status.The oncologist · 2025Article
- Correlation between BRCA1 expression and the advanced stage of triple‑negative breast cancer.Molecular and clinical oncology · 2025Article
- Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.BMC medicine · 2024Article
- Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer.Cancer medicine · 2023Article
- Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations.Discover oncology · 2023Review
- Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine.Breast cancer research and treatment · 2022Article
- Prognostic Prediction of BRCA Mutations byMolecular imaging and radionuclide therapy · 2021Article
- Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach.Diagnostics (Basel, Switzerland) · 2021Article
- Prognostic Impact ofBiology · 2021Article
- Effects ofJournal of oncology · 2020Article
- Article
- Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review.Hereditary cancer in clinical practice · 2018Article
- Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features.BMC women's health · 2016Article
- Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer.Oncotarget · 2016Article
- Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.Journal of cancer research and clinical oncology · 2016Article
- Integrating mutation and gene expression cross-sectional data to infer cancer progression.BMC systems biology · 2016Article
- Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.PloS one · 2016Article
- High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients.Hereditary cancer in clinical practice · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is proposed to be an immunohistochemical surrogate of the basal-like breast cancer subtype. In spite of the relative chemosensitivity of this cancer subtype, it is characterized by aggressive clinical behavior; therefore, a further subclassification of TNBC is required to develop new targeted treatment. In previous studies, a strong correlation between
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.